Paul Workman

Cancer Research UK (GB)

Research Areas

BiologyChemistryMedicineGeneticsBiochemistryInternal medicineCancer researchCell biology

Discover Papers by Paul Workman

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

105

Publications

1186

Citations

45126

i10-index

473

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Patient-derived organoids model treatment response...	2018	1543
Guidelines for the welfare and use of animals in c...	2010	1322
Combinatorial drug therapy for cancer in the post-...	2012	989
Imaging biomarker roadmap for cancer studies	2016	941
Hsp90 Molecular Chaperone Inhibitors: Are We There...	2012	815
Challenges to curing primary brain tumours	2019	757
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6...	2008	729
Discovery of small molecule cancer drugs: Successe...	2012	545
Targeting the PI3K–AKT–mTOR pathway: progress, pit...	2008	535
HSP90 as a new therapeutic target for cancer thera...	2002	530

Publications

1.
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Year: 2018Citations: 1543DOI: 10.1126/science.aao2774
2.
Guidelines for the welfare and use of animals in cancer research
Year: 2010Citations: 1322DOI: 10.1038/sj.bjc.6605642
3.
Combinatorial drug therapy for cancer in the post-genomic era
Year: 2012Citations: 989DOI: 10.1038/nbt.2284
4.
Imaging biomarker roadmap for cancer studies
Year: 2016Citations: 941DOI: 10.1038/nrclinonc.2016.162
5.
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Year: 2012Citations: 815DOI: 10.1158/1078-0432.ccr-11-1000
6.
Challenges to curing primary brain tumours
Year: 2019Citations: 757DOI: 10.1038/s41571-019-0177-5
7.
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Year: 2008Citations: 729DOI: 10.1021/jm800295d
8.
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Year: 2012Citations: 545DOI: 10.1016/j.molonc.2012.02.004
9.
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Year: 2008Citations: 535DOI: 10.1016/j.coph.2008.08.004
10.
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Year: 2002Citations: 530DOI: 10.1517/14712598.2.1.3

About Paul Workman

Paul Workman is a researcher with 1186 publications and 45126 citations. They are affiliated with Cancer Research UK. Their research focuses on Biology, Chemistry, Medicine and other areas. With an h-index of 105, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Paul Workman and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year